Study guide

24.3 Audits, Inspections and Closure Planning

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

24.3 Audits, Inspections and Closure Planning

Key Takeaways Explain This Topic AI

Independent audits differ from routine monitoring and authority inspections.

Preparation means locating truthful existing evidence, not manufacturing a clean history.

Global database lock is not a universal prerequisite to every site close-out.

Last updated: October 2026

Audits, Inspections and Closure Planning

Under ICH E6(R3), if non-compliance that significantly affects or has the potential to significantly affect human subject protection or trial integrity is discovered, the sponsor must perform a formal Root Cause Analysis (RCA) and implement appropriate Corrective and Preventive Actions (CAPA) .

Root Cause Analysis: Rather than simply punishing an individual error, the CRA and site examine systemic factors using structured methodologies such as the 5 Whys Technique or the Ishikawa (Fishbone) Diagram . RCA explores whether the failure stemmed from inadequate staffing, ambiguous protocol language, lack of role-specific training, software malfunction, or cognitive misunderstanding.

CAPA Architecture: Corrective actions remediate the immediate historical defect (e.g., re-consenting affected subjects, performing omitted safety labs), while preventive actions modify standard operating procedures, implement automated scheduling safeguards, or mandate re-training to prevent future recurrence.

Risk-proportionate escalation

The sponsor should act promptly, evaluate causes and implement appropriate remediation. Serious risks may require immediate escalation or a pause; do not insist on a fixed sequence of informal counselling before protecting participants. If significant noncompliance persists despite remediation efforts, E6(R3) says the sponsor should consider terminating participation and notify relevant authorities/ethics bodies as appropriate. It is not an automatic rule that every serious finding immediately terminates a site.

The investigator and sponsor must plan continuity of care and reliable records if participation is suspended or ended. A pause should specify its scope: recruitment, screening, dosing, procedures or a particular cohort. Protect participants from both continued unsafe activity and abrupt withdrawal of necessary care. Document decisions, responsibilities, communication and resumption conditions.

Sponsor audits and authority inspections

An audit is an independent systematic examination, separate from routine monitoring or quality control, to evaluate trial-related activities and records. An inspection is an official review by a regulatory authority. Both require truthful cooperation and accessible evidence, but their authority and reporting processes differ.

Activity Primary role CRA contribution

Monitoring Ongoing oversight of trial/site processes under the plan Detect and communicate issues; track follow-up

Independent audit Evaluate systems and compliance independently of routine operations Facilitate access and factual context without controlling the auditor's findings

Regulatory inspection Official authority review Support the site/sponsor response process and preserve records

Before a review, locate the current protocol and approval history, source records, consent evidence, qualifications, product records, monitoring communications and unresolved issue records. Identify a records coordinator and ensure authorised access works. Preparation means organising existing evidence, not manufacturing records or backdating missing signatures.

During the review, answer within your knowledge, distinguish observed facts from inference and retrieve requested records through the documented process. If an answer is unknown, obtain it rather than speculate. Do not coach staff to hide concerns or replace an original record with a cleaner undocumented version. Preserve participant confidentiality and the blind while respecting lawful authorised access.

After findings are received, the responsible entity reviews the evidence, evaluates immediate risk, investigates causes and assigns corrective actions, owners and deadlines. Responses should address each finding with supporting evidence and an appropriate effectiveness plan. Follow the actual authority/audit communication deadline; a national form number or 15-business-day policy is not a universal ICH examination rule. The CRA can facilitate follow-up within their assigned role without approving independent audit conclusions.

Site Close-Out Visit (COV) Execution & Archiving under E6(R3)

The Site Close-Out Visit (COV) is the final on-site monitoring milestone conducted by the CRA, marking the formal conclusion of the clinical investigation at that participating institution.

Planning closure against the actual trial status

A close-out visit can occur at different stages according to the sponsor's plan, including early termination. Global database lock is not a universal prerequisite . Determine what can be completed and what remains: participant follow-up, unresolved safety information, queries, product reconciliation, essential records, site data retention and continued access. Assign outstanding work explicitly rather than pretending that closure erases it.

Confirm participant care and notifications, authorised product/supply disposition, study equipment return, relevant final reports and appropriate archive arrangements. Do not return a device or terminate a portal before required data and metadata have been preserved. A remote close-out can be appropriate when the objectives can be achieved; a visit label alone does not prove closure.

  • Detailed Step-by-Step Close-Out Procedures
  • Product disposition

Reconcile products using mutually exclusive stock categories, accounting for participant returns separately from consumption. Follow sponsor-authorised return or destruction procedures and investigate discrepancies. The evidence should identify quantities, batches/kit identifiers, disposition and responsible parties. Do not count a returned participant tablet both as consumed and as returned to the depot.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 .